BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26633622)

  • 1. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
    Olivieri I; Cortesi PA; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Ciampichini R; Cutro MS; Mathieu A; Matucci-Cerinic M; Punzi L; Scarpa R; Mantovani LG;
    Clin Exp Rheumatol; 2016; 34(1):68-75. PubMed ID: 26633622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.
    Olivieri I; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Cutro MS; Mathieu A; Matucci-Cerinic M; Pappone N; Punzi L; Scarpa R; Mantovani LG;
    Rheumatology (Oxford); 2008 Nov; 47(11):1664-70. PubMed ID: 18725374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic issues in psoriatic arthritis.
    Olivieri I; D'Angelo S; Palazzi C; Padula A; Lubrano E; Mantovani LG
    J Rheumatol Suppl; 2012 Jul; 89():103-5. PubMed ID: 22751607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.
    Kirkham B; de Vlam K; Li W; Boggs R; Mallbris L; Nab HW; Tarallo M
    Clin Exp Rheumatol; 2015; 33(1):11-9. PubMed ID: 25535650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept in psoriatic arthritis.
    Spadaro A; Lubrano E; Ferrara N; Scarpa R
    J Rheumatol Suppl; 2012 Jul; 89():74-6. PubMed ID: 22751599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM; Marchesoni A; Lubrano E
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.
    Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
    Ann Rheum Dis; 2010 Feb; 69(2):352-7. PubMed ID: 19282310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
    Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Koldingsnes W; Mowinckel P; Kvien TK
    Ann Rheum Dis; 2007 Aug; 66(8):1038-42. PubMed ID: 17213251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
    Simone D; Nowik M; Gremese E; Ferraccioli GF
    J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
    Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
    J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalassemic trait prevalence in patients affected by psoriatic arthritis in anti-TNF treatment.
    Atteno M; Costa L; Vitiello M; Caso F; Sarnelli G; Del Puente A; Scarpa R
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S20-2. PubMed ID: 25381968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis--effect of different treatments.
    Di Minno MN; Iervolino S; Peluso R; Di Minno A; Ambrosino P; Scarpa R;
    J Rheumatol; 2014 Apr; 41(4):714-22. PubMed ID: 24532831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A higher score on the dermatology life quality index, being on systemic treatment and having a diagnosis of psoriatic arthritis is associated with increased costs in patients with plaque psoriasis.
    Ekelund M; Mallbris L; Qvitzau S; Stenberg B
    Acta Derm Venereol; 2013 Nov; 93(6):684-8. PubMed ID: 23603935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of low disease activity and remission in psoriatic arthritis.
    Lubrano E; Perrotta FM; Kavanaugh A
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S51-4. PubMed ID: 26470835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).
    Kavanaugh A; Mease P
    J Rheumatol Suppl; 2012 Jul; 89():90-3. PubMed ID: 22751603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
    Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
    Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.